

Advaxis is a leader in developing the next generation of immunotherapies that are designed to harness the body’s intrinsic ability to fight cancer and infectious diseases. The company has fifteen (15) constructs in various stages of development.

Advaxis’ technology platform is intended to direct the innate human immune response to simultaneously stimulate a comprehensive immune attack and overcome tumor protection mechanisms.

Clinical Pipeline

CONSTRUCT	INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2
ADXS-HPV	CIN (Cervical Dysplasia) 2/3			
ADXS-HPV	Cervical Cancer, US, NCI/GOG			
ADXS-HPV	Cervical Cancer, India			
ADXS-HPV	Head & Neck Cancer, UK, CRUK			
ADXS-PSA	Prostate Cancer			
ADXS-HER2	Breast & Other Cancers			
ADXS-HER2	Canine Osteosarcoma, UPenn			

Board of Directors	Management Team	Stock Snapshot	(December 7, 2011)
Thomas A. Moore	Thomas A. Moore	Stock Price	0.16
Dr. James Patton	Dr. John Rothman	52wk Range	0.11-0.25
Roni A. Appel	Mark Rosenblum	Market Cap	39.89M
Dr. Thomas McKearn	Dr. Robert Petit	Shares O/S	241.92M
Richard Berman	Chris French	Avg Volume	496,302

Technology

Advaxis immunotherapies are based on a novel platform technology using live attenuated *Listeria monocytogenes (Lm)* that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to *Lm* to the cancer itself.

Intellectual Property Portfolio

- Over 70 patents issued, filed, & pending worldwide
- Patents cover compositions of matter, method, & use

Forward-Looking Statements. Statements that state the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. It is important to note that the Company’s actual results could differ materially from those projected in such forward-looking statements.

ADVAXIS, INC.
 305 College Road East
 Princeton, NJ 08540
 Phone: 609.452.9813
 www.advaxis.com

